Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +26.40p +1.61% 1,665.00p 1,663.60p 1,664.20p 1,672.00p 1,645.40p 1,646.60p 10,868,251 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.0 4,048.0 73.7 22.6 -

Glaxosmithkline Share Discussion Threads

Showing 19501 to 19522 of 19875 messages
Chat Pages: Latest  783  782  781  780  779  778  777  776  775  774  773  772  Older
DateSubjectAuthorDiscuss
26/3/2019
15:13
Hardly crowing ...and certainly not multiple posting as you were predicting where this share price was/is going ...in the meantime I'm happy to see it where it is ....ttfn
badtime
25/3/2019
22:41
Perhaps it's worth remembering that at 10-00 the night before brexit vote was confirmed you could get 5-1 on it happeningAlso Donald Trump was 6-1 to beat Hilary the day before The bookies do screw up sometimes!
mattboxy
25/3/2019
11:39
Not sure why bedtime is crowing. GSK still going nowhere
zicopele
22/3/2019
09:25
Thanks steeplejack, good thought. The serious money always has a better idea of how things are really going than the newspapers do.
grahamite2
22/3/2019
08:44
(Sorry again Spud) The Betfair odds on a No Deal are 11/4...not very short odds,
steeplejack
22/3/2019
07:43
I don't think we need to worry about Brexit. Due to NI situation it's impossible to enact a true Brexit (hence backstop) and leaving without a deal seems unlikely. They will kick the can down the road either through Backstop or a new deal. It will go on for years but trading conditions won't change that much. All very depressing but nobody thought about NI at the time of the vote so nobody realised that unless NI leaves UK or is treated differently proper Brexit as described at the time of the vote cannot happen.
amt
21/3/2019
18:43
Sogoes...him and the other bod Zico something or other......totally silent because they called it wrong
badtime
21/3/2019
17:25
Fine update from DREAMM-1 👍
philanderer
21/3/2019
16:05
If only montyhedge were here to confirm such a recovery we might believe it were true! ;-)
sogoesit
21/3/2019
16:03
Sorry Spud.Whole sector is strong.AstraZeneca has hit a years high and Smith&Nephew is only a few coppers shy.Suggests that GSK might have further to run.There's apparent technical resistance at 1568.See if we can get through that barrier.
steeplejack
21/3/2019
15:53
Meantime, on the GSK thread (which i believe this is although you could be forgiven for thinking its a BREXIT one) GSK continues to recover. spud
spud
21/3/2019
15:50
Teresa May(or should we call her Thelma)seems quite prepared to drive the UK over the cliff with No Deal unless her flawed plan is voted through.I'm very surprised that the prime ministerial position as an office has such dictatorial power.She's now behaving in a rather feral manner and frankly I'm a little worried about her health.She's certainly earned a holiday.A good long break in Elba or St Helena spring to mind.
steeplejack
21/3/2019
13:06
FIO. Bad news for patients. A very difficult disease area, but big rewards if someone gets there. This was in Phase III btw. Biogen shares plunge nearly 30% after ending trial for potential blockbuster Alzheimer's drug Aducanumab.
alphorn
21/3/2019
12:24
Good post sogoesit. Yes, she probably would have made a first-rate clerk in the DHSS or something.
grahamite2
21/3/2019
11:39
Yep, failure to read and understand the opposition's position and their perception of you in a negotiation is an amateur mistake but all too common. Having your own world-view in mind, and assuming it to be the same as other cultures', is pervasive in us humans and in a lot of commercial negotiations. If you don't understand another's culture better find someone who can or seek help. May is, imv, a bureacratic servant with historical (her background) "factual" views not suited to imagining the benefits that arise from short term destabilisation that can be used to reset strategy. Apart from the fact that she appears to be a pathological liar which is not a useful behaviour to have as a negotiator! (It was always clear that, strategically, the EU would seek to punish an exiting nation if only for its self-protection).
sogoesit
20/3/2019
22:05
Oh dear,the French are such a disappointment.They fail to understand the British mentality.Churchill spoke to the Canadian Parliament in 1941 and told them how the French military leaders behaved a year earlier: "When I warned them that Britain would fight on alone, whatever they did, their generals told their Prime Minister and his divided cabinet, "In three weeks England will have her neck wrung like a chicken". Some chicken (huge cheers). Some neck!" (more cheers and applause).I hold May largely responsible for the current impasse but ultimately the blame might well be laid at the EU's door for being intransigent.I voted remain but I increasingly feel we should just leave without a deal.The EU seems to forget that we'll still be the EU's largest trading partner even after we've left.
steeplejack
20/3/2019
13:09
Moving as a hedge again now as GBP falls. A good share for a GBP based investor to hold.
alphorn
20/3/2019
13:08
Sp has been pretty stable last few weeks which has quietened a couple of posters
badtime
20/3/2019
10:44
TM, thanks for this information. Maybe, just maybe, it is starting to awake this morning!
jadeticl3
20/3/2019
09:59
I think that GSK is sitting on a goldmine of new immuno-oncology drugs with the acquisition of Tesaro, as the results of clinical trials start to filter through during 2019. GSK recognised this in the massive investment made through the purchase of this asset. The market has yet to wake up to the value of this opportunity.
tradermichael
20/3/2019
09:48
For information, there is a former tie-up between Tesaro and a company called AnaptysBio TESARO Partnership Under our immuno-oncology collaboration with TESARO, we have granted exclusive rights to TESARO to develop and commercialize the following AnaptysBio-generated antibody product candidates: Anti-PD-1 Monospecific Antagonist Antibody (Dostarlimab, TSR-042): BLA Filing Anticipated in H2 2019; Anti-TIM-3 Monospecific Antagonist Antibody (TSR-022): Dose escalation completed in Phase 1, combination trial with TSR-042 has been initiated; Anti-LAG-3 Monospecific Antagonist Antibody (TSR-033): Phase 1 trial initiated, and Anti-PD-1/LAG-3 Bispecific Antagonist Antibody (TSR-075): lead candidate identified, IND-enabling studies on-going.
tradermichael
19/3/2019
19:40
GlaxoSmithKline PLC on Tuesday said data from the early-stage Garnet clinical study had promising results for the use of Dostarlimab in patients...
abdullla
Chat Pages: Latest  783  782  781  780  779  778  777  776  775  774  773  772  Older
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190716 22:40:13